Aptuit LLC has begun a growth program for 2016 to meet demand from in discovery, chemistry, manufacturing and controls (CMC) and non-clinical development. During 2016, Aptuit will hire an additional 90 scientists to its facilities in Oxford, UK and Verona, Italy, distributed across all areas. In addition, the company will invest $16 million for facility upgrades and equipment to enhance its integrated development capabilities.

Aptuit's existing expertise in drug design & discovery will be strengthened with additional capacity and targeted investments in Hit Identification solutions, translational, and biomarkers capabilities and late lead optimization strategies. CMC will be strengthened with additional technologies in clinical manufacturing, in particular to its tableting and encapsulating; increasing the footprint and capabilities of its formulation development facilities to further expand Aptuit's capability to successfully develop poorly soluble products; and specific investments in quality control and material sciences.

Source: Aptuit